AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting First patient enrolled in Phase III clinical trial for moxetumomab pasudotox as a treatment for unresponsive or relapsed hairy cell leukaemia patients.
Olaparib planned to progress to Phase III for platinum-sensitive relapsed ovarian cancer patients with BRCA mutations in 2013.
Selumetinib planned to progress to Phase III for non small cell lung cancer patients with KRAS mutations in 2013.
AstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III clinical development. As set out at its Investor Day in March, oncology is one of the company’s core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority.
AstraZeneca PLC first quarter results 2013 Pascal Soriot, Chief Executive Officer, commenting on the results, said: "As anticipated, the first quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership. Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets."
MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.
AstraZeneca settles litigation over CRESTOR patent AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals regarding Watson’s proposed rosuvastatin zinc product. Watson, a successor of Cobalt, also agreed not to further appeal a decision by the U.S. Court of Appeals for the Federal Circuit that upheld the validity and enforceability of the CRESTOR® (rosuvastatin calcium) substance patent. Shionogi is also a party to the settlement agreement.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.